André P. Fay
Hospital São Lucas da PUCRS(BR)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, Renal and related cancers, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy
Most-Cited Works
- → Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial(2021)635 cited
- → Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial(2020)489 cited
- → Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial(2023)464 cited
- → Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma(2015)341 cited
- → PD-L1 expression in nonclear-cell renal cell carcinoma(2014)298 cited
- → Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma(2015)277 cited
- → Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial(2014)244 cited
- → A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma(2014)235 cited
- → Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma(2016)225 cited
- → Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations(2016)214 cited